StockMacro
Company, fund or insider

Help

Menu

Quest Diagnostics

$258.28 +34% in 6 monthsMarket cap $28.4B

DGX on XNYS, Health Care, Quest Diagnostics Inc., job postings

Measures activity, not value. Not investment advice.

Net income rose 17% to $1.1B over 12 months as latest quarter revenue grew 10%.

  • GoodInstitutional holders up 4.1% to 1,126 filers in the latest quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Industry
Services-medical laboratories (Health Care)
Employees
57,000
Website
questdiagnostics.com
Listed
NYSE, US
Last results
22 Oct 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $3.1B, net income $312.0M.
Quarter to 31 Dec 2021: revenue $2.7B, net income $390.0MQuarter to 31 Dec 2021: revenue $2.7B, net income $390.0MQuarter to 31 Mar 2022: revenue $2.6B, net income $355.0MQuarter to 31 Mar 2022: revenue $2.6B, net income $355.0MQuarter to 30 Jun 2022: revenue $2.5B, net income $234.0MQuarter to 30 Jun 2022: revenue $2.5B, net income $234.0MQuarter to 30 Sep 2022: revenue $2.5B, net income $256.0MQuarter to 30 Sep 2022: revenue $2.5B, net income $256.0MQuarter to 31 Dec 2022: revenue $2.3B, net income $101.0MQuarter to 31 Dec 2022: revenue $2.3B, net income $101.0MQuarter to 31 Mar 2023: revenue $2.3B, net income $202.0MQuarter to 31 Mar 2023: revenue $2.3B, net income $202.0MQuarter to 30 Jun 2023: revenue $2.3B, net income $235.0MQuarter to 30 Jun 2023: revenue $2.3B, net income $235.0MQuarter to 30 Sep 2023: revenue $2.3B, net income $225.0MQuarter to 30 Sep 2023: revenue $2.3B, net income $225.0MQuarter to 31 Dec 2023: revenue $2.3B, net income $192.0MQuarter to 31 Dec 2023: revenue $2.3B, net income $192.0MQuarter to 31 Mar 2024: revenue $2.4B, net income $194.0MQuarter to 31 Mar 2024: revenue $2.4B, net income $194.0MQuarter to 30 Jun 2024: revenue $2.4B, net income $229.0MQuarter to 30 Jun 2024: revenue $2.4B, net income $229.0MQuarter to 30 Sep 2024: revenue $2.5B, net income $226.0MQuarter to 30 Sep 2024: revenue $2.5B, net income $226.0MQuarter to 31 Dec 2024: revenue $2.6B, net income $222.0MQuarter to 31 Dec 2024: revenue $2.6B, net income $222.0MQuarter to 31 Mar 2025: revenue $2.7B, net income $220.0MQuarter to 31 Mar 2025: revenue $2.7B, net income $220.0MQuarter to 30 Jun 2025: revenue $2.8B, net income $282.0MQuarter to 30 Jun 2025: revenue $2.8B, net income $282.0MQuarter to 30 Sep 2025: revenue $2.8B, net income $245.0MQuarter to 30 Sep 2025: revenue $2.8B, net income $245.0MQuarter to 31 Dec 2025: revenue $2.8B, net income $245.0MQuarter to 31 Dec 2025: revenue $2.8B, net income $245.0MQuarter to 31 Mar 2026: revenue $2.9B, net income $252.0MQuarter to 31 Mar 2026: revenue $2.9B, net income $252.0MQuarter to 30 Jun 2026: revenue $3.0B, net income $320.0MQuarter to 30 Jun 2026: revenue $3.0B, net income $320.0MQuarter to 30 Sep 2026: revenue $3.1B, net income $312.0MQuarter to 30 Sep 2026: revenue $3.1B, net income $312.0M
31 Dec 2021RevenueNet incometallest bar $3.1B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$3.1B$312.0M
30 Jun 2026$3.0B$320.0M
31 Mar 2026$2.9B$252.0M
31 Dec 2025$2.8B$245.0M
30 Sep 2025$2.8B$245.0M
30 Jun 2025$2.8B$282.0M
31 Mar 2025$2.7B$220.0M
31 Dec 2024$2.6B$222.0M
30 Sep 2024$2.5B$226.0M
30 Jun 2024$2.4B$229.0M
31 Mar 2024$2.4B$194.0M
31 Dec 2023$2.3B$192.0M
30 Sep 2023$2.3B$225.0M
30 Jun 2023$2.3B$235.0M
31 Mar 2023$2.3B$202.0M
31 Dec 2022$2.3B$101.0M
30 Sep 2022$2.5B$256.0M
30 Jun 2022$2.5B$234.0M
31 Mar 2022$2.6B$355.0M
31 Dec 2021$2.7B$390.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $11.8B $10.8B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +9.1% +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.1B $969.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $10.04 $8.52
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 33.1% 33.3% 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 14.6% 14.1% -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 9.5% 8.9% -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 15.2% -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $1.4B $1.4B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $797.0M $432.0M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $5.5B $5.7B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $4.8B $5.2B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.73 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $69.37
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 25.2 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. 2.4 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 2.8 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.7 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Quest DiagnosticsDGX (this company) $28.4B25.22.4+9.1%9.5%
LabcorpLH $29.8B29.72.0+6.0%6.9%
NateraNTRA $39.6Bloss13.6+37%-5.7%
Guardant HealthGH $19.7Bloss15.4+42%-37.9%
RadNetRDNT $5.5Bloss2.3+21%-0.9%
Caris Life SciencesCAI $5.0B52.54.8+61%9.2%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+10%

$3.1B vs $2.8B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+15%

$166.0M vs $144.0M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$19.8M

bought $0, sold $19.8M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+4.1%

1,126 13F filers vs 1,082

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

93%

102.6M shares held by 13F filers (30 Sep 2026) of 110.0M outstanding (15 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

3.4%

3.7M shares sold short (30 Oct 2026) of 110.0M outstanding (15 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.6

3.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.5%

3.6M shares sold short in the report before, 3.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

59%

59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+6.5%

49 vs 46 applications

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$67.0M

the 12 months before: $63.3M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$300K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

52

52 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.7×

52 articles in the last 7 days; its usual week has 6.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Federal obligations $57.0M, 1.3× a year earlier

Price $258.28 on 20 Nov 2026, +38% over 12 months (12-month range $173.49 to $262.21)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $36.5M in the last 12 months (the 12 months before: -$43.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 49 published in the last 12 months, +6.5% on the 12 months before.
Revenue per quarter. Revenue $3.1B in the latest quarter, +10% on a year earlier.
Capital spending per quarter. Capital spending $166.0M in the latest quarter, +15% on a year earlier.
Institutional holders (13F filers). 1,126 13F filers reported holding it in the latest 13F quarter, +18% on a year earlier.
Federal obligations. Federal obligations: $77.9M published in the last 12 months, +30% on the 12 months before.
Lobbying spend. Lobbying spend: $300K published in the last 12 months (none in the 12 months before).
Workers in WARN layoff notices. Workers in WARN layoff notices: 0 published in the last 12 months, -100% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Nov 2026Sharp changeFederal obligations jump: federal obligations jump, 57.0M vs usual 35.6M in the same month of earlier years (2026-10-01..2026-10-31); 1.3x the same month a year earlier
6 Oct 20268-K and other filingsDirector or officer change
6 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Mar 20268-K and other filingsDirector or officer change
12 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Aug 2025Sharp changeShort interest spike: short interest spike, 4.7M vs usual 2.6M (2025-07-31); 2.0x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 4.6M vs usual 2.6M (2025-07-15); 2.0x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 3.8M vs usual 2.5M (2025-05-30); 1.4x the same period a year earlier
3 Jun 2025Sharp changeShort interest spike: short interest spike, 3.9M vs usual 2.5M (2025-05-15); 1.4x the same period a year earlier
1 Jun 2025WARN layoff noticeQuest Diagnostics, Inc., 121 workers, Montgomery, PA
1 Jun 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 121)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 118 vs usual 58.50 (2025-03-31); 1.8x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 4.0M vs usual 2.5M (2025-04-30); 1.4x the same period a year earlier
21 May 20248-K and other filingsDirector or officer change
21 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Apr 2024Sharp changeFederal obligations jump: federal obligations jump, 21.4M vs usual 2.9M in the same month of earlier years (2024-03-01..2024-03-31); 2.1x the same month a year earlier
29 Sep 20238-K and other filingsDirector or officer change
29 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Apr 2023Lobbying filinglobbying engagement terminated (KING & SPALDING LLP)
30 Mar 2023Lobbying filingnew lobbying registration (TARPLIN, DOWNS & YOUNG, LLC)
7 Feb 2023Sharp changeFederal obligations jump: federal obligations jump, 31.0M vs usual 7.8M in the same month of earlier years (2023-01-01..2023-01-31); 2.7x the same month a year earlier
18 Nov 20228-K and other filingsDirector or officer change
1 Nov 20228-K and other filingsDirector or officer change
28 Oct 20228-K and other filingsDirector or officer change
28 Oct 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Jul 2022Sharp changeFederal obligations jump: federal obligations jump, 69.2M vs usual 7.1M in the same month of earlier years (2022-06-01..2022-06-30); 9.7x the same month a year earlier
14 Jun 20228-K and other filingsDirector or officer change
7 Jun 2022Sharp changeFederal obligations jump: federal obligations jump, 43.2M vs usual 1.8M in the same month of earlier years (2022-05-01..2022-05-31); 3.5x the same month a year earlier
25 May 20228-K and other filingsDirector or officer change
21 Apr 2022Sharp changeLobbying on a new issue: lobbying on a new issue: BUD (2022-03-31)
12 Apr 2022Sharp changeFederal obligations jump: federal obligations jump, 21.9M vs usual 2.9M in the same month of earlier years (2022-03-01..2022-03-31); 7.5x the same month a year earlier
2 Mar 20228-K and other filingsDirector or officer change
1 Mar 20228-K and other filingsDirector or officer change
3 Feb 20228-K and other filingsDirector or officer change
3 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Jan 2022Sharp changeLobbying spend jump: lobbying spend jump, 950K vs usual 225K (2021-12-31); 4.3x the same period a year earlier
Insider net buying (open market)
Month from 1 Dec 2021: -$5.9M published
Month from 1 Mar 2022: -$2.4M published
Month from 1 May 2022: -$61.0M published
Month from 1 Jul 2022: -$267K published
Month from 1 Aug 2022: -$272K published
Month from 1 Sep 2022: -$250K published
Month from 1 Oct 2022: -$2.5M published
Month from 1 Nov 2022: -$6.4M published
Month from 1 Dec 2022: -$309K published
Month from 1 Feb 2023: -$439K published
Month from 1 Mar 2023: -$1.6M published
Month from 1 Feb 2024: -$504K published
Month from 1 Mar 2024: -$1.6M published
Month from 1 May 2024: -$246K published
Month from 1 Jul 2024: -$60K published
Month from 1 Aug 2024: -$305K published
Month from 1 Sep 2024: -$5.0M published
Month from 1 Oct 2024: -$279K published
Month from 1 Nov 2024: -$2.9M published
Month from 1 Dec 2024: -$11.1M published
Month from 1 Feb 2025: -$674K published
Month from 1 Mar 2025: -$2.2M published
Month from 1 Apr 2025: -$7.0M published
Month from 1 May 2025: -$307K published
Month from 1 Aug 2025: -$4.3M published
Month from 1 Sep 2025: -$5.3M published
Month from 1 Oct 2025: -$313K published
Month from 1 Nov 2025: -$12.3M published
Month from 1 Feb 2026: -$7.3M published
Month from 1 Mar 2026: -$5.5M published
Month from 1 Jun 2026: -$3.6M published
Month from 1 Jul 2026: -$376K published
Month from 1 Sep 2026: -$7.9M published
Month from 1 Oct 2026: -$292K published
Month from 1 Nov 2026: -$11.6M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 10 published
Quarter from 1 Apr 2022: 11 published
Quarter from 1 Jul 2022: 20 published
Quarter from 1 Oct 2022: 18 published
Quarter from 1 Jan 2023: 9 published
Quarter from 1 Apr 2023: 8 published
Quarter from 1 Jul 2023: 9 published
Quarter from 1 Oct 2023: 16 published
Quarter from 1 Jan 2024: 6 published
Quarter from 1 Apr 2024: 9 published
Quarter from 1 Jul 2024: 7 published
Quarter from 1 Oct 2024: 6 published
Quarter from 1 Jan 2025: 11 published
Quarter from 1 Apr 2025: 12 published
Quarter from 1 Jul 2025: 11 published
Quarter from 1 Oct 2025: 12 published
Quarter from 1 Jan 2026: 6 published
Quarter from 1 Apr 2026: 8 published
Quarter from 1 Jul 2026: 15 published
Quarter from 1 Oct 2026: 20 published
Revenue per quarter
Quarter ended 31 Dec 2021: $2.7B, -8.6% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $2.6B, -4.0% on a year earlier; public on 23 Apr 2022
Quarter ended 30 Jun 2022: $2.5B, -3.8% on a year earlier; public on 23 Jul 2022
Quarter ended 30 Sep 2022: $2.5B, -10% on a year earlier; public on 22 Oct 2022
Quarter ended 31 Dec 2022: $2.3B, -15% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $2.3B, -11% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $2.3B, -4.7% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $2.3B, -7.7% on a year earlier; public on 26 Oct 2023
Quarter ended 31 Dec 2023: $2.3B, -1.9% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $2.4B, +1.5% on a year earlier; public on 25 Apr 2024
Quarter ended 30 Jun 2024: $2.4B, +2.5% on a year earlier; public on 25 Jul 2024
Quarter ended 30 Sep 2024: $2.5B, +8.4% on a year earlier; public on 24 Oct 2024
Quarter ended 31 Dec 2024: $2.6B, +15% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $2.7B, +12% on a year earlier; public on 24 Apr 2025
Quarter ended 30 Jun 2025: $2.8B, +15% on a year earlier; public on 24 Jul 2025
Quarter ended 30 Sep 2025: $2.8B, +13% on a year earlier; public on 22 Oct 2025
Quarter ended 31 Dec 2025: $2.8B, +7.1% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $2.9B, +9.2% on a year earlier; public on 23 Apr 2026
Quarter ended 30 Jun 2026: $3.0B, +10% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $3.1B, +10% on a year earlier; public on 24 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $144.0M, -11% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $63.0M, -27% on a year earlier; public on 23 Apr 2022
Quarter ended 30 Jun 2022: $76.0M, -9.5% on a year earlier; public on 23 Jul 2022
Quarter ended 30 Sep 2022: $118.0M, +33% on a year earlier; public on 22 Oct 2022
Quarter ended 31 Dec 2022: $147.0M, +2.1% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $127.0M, +102% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $104.0M, +37% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $105.0M, -11% on a year earlier; public on 26 Oct 2023
Quarter ended 31 Dec 2023: $72.0M, -51% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $104.0M, -18% on a year earlier; public on 25 Apr 2024
Quarter ended 30 Jun 2024: $92.0M, -12% on a year earlier; public on 25 Jul 2024
Quarter ended 30 Sep 2024: $106.0M, +1.0% on a year earlier; public on 24 Oct 2024
Quarter ended 31 Dec 2024: $123.0M, +71% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $117.0M, +12% on a year earlier; public on 24 Apr 2025
Quarter ended 30 Jun 2025: $108.0M, +17% on a year earlier; public on 24 Jul 2025
Quarter ended 30 Sep 2025: $144.0M, +36% on a year earlier; public on 22 Oct 2025
Quarter ended 31 Dec 2025: $158.0M, +28% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $114.0M, -2.6% on a year earlier; public on 23 Apr 2026
Quarter ended 30 Jun 2026: $138.0M, +28% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $166.0M, +15% on a year earlier; public on 24 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 795; public on 14 Feb 2022
31 Mar 2022 report: 796; public on 16 May 2022
30 Jun 2022 report: 799; public on 15 Aug 2022
30 Sep 2022 report: 735; public on 14 Nov 2022
31 Dec 2022 report: 803; public on 14 Feb 2023
31 Mar 2023 report: 766; public on 15 May 2023
30 Jun 2023 report: 746; public on 14 Aug 2023
30 Sep 2023 report: 731; public on 14 Nov 2023
31 Dec 2023 report: 762; public on 14 Feb 2024
31 Mar 2024 report: 768; public on 15 May 2024
30 Jun 2024 report: 794; public on 14 Aug 2024
30 Sep 2024 report: 794; public on 14 Nov 2024
31 Dec 2024 report: 852; public on 14 Feb 2025
31 Mar 2025 report: 917; public on 15 May 2025
30 Jun 2025 report: 943; public on 14 Aug 2025
30 Sep 2025 report: 952; public on 14 Nov 2025
31 Dec 2025 report: 1,005; public on 17 Feb 2026
31 Mar 2026 report: 1,038; public on 15 May 2026
30 Jun 2026 report: 1,082; public on 14 Aug 2026
30 Sep 2026 report: 1,126; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $722K published
Month from 1 Dec 2021: $4.0M published
Month from 1 Jan 2022: $11.9M published
Month from 1 Feb 2022: $2.5M published
Month from 1 Mar 2022: $19.9M published
Month from 1 Apr 2022: $6.0M published
Month from 1 May 2022: $44.4M published
Month from 1 Jun 2022: $12.3M published
Month from 1 Jul 2022: $62.8M published
Month from 1 Aug 2022: $1.3M published
Month from 1 Sep 2022: $3.5M published
Month from 1 Oct 2022: $34.1M published
Month from 1 Nov 2022: $15.2M published
Month from 1 Dec 2022: $9.7M published
Month from 1 Jan 2023: $31.7M published
Month from 1 Feb 2023: $1.6M published
Month from 1 Mar 2023: $11.1M published
Month from 1 Apr 2023: $578K published
Month from 1 May 2023: $13.2M published
Month from 1 Jun 2023: $25.6M published
Month from 1 Jul 2023: $3.5M published
Month from 1 Aug 2023: $585K published
Month from 1 Sep 2023: -$9.5M published
Month from 1 Oct 2023: $35.4M published
Month from 1 Nov 2023: $8.7M published
Month from 1 Dec 2023: $2.5M published
Month from 1 Jan 2024: $10.8M published
Month from 1 Feb 2024: -$606K published
Month from 1 Mar 2024: $5.3M published
Month from 1 Apr 2024: $20.5M published
Month from 1 May 2024: $3.9M published
Month from 1 Jun 2024: -$705K published
Month from 1 Jul 2024: -$1.4M published
Month from 1 Aug 2024: $8.8M published
Month from 1 Sep 2024: $3.8M published
Month from 1 Oct 2024: $36.0M published
Month from 1 Nov 2024: $4.8M published
Month from 1 Dec 2024: $3.5M published
Month from 1 Jan 2025: $3.7M published
Month from 1 Feb 2025: $5.4M published
Month from 1 Mar 2025: $28.9M published
Month from 1 Apr 2025: $2.1M published
Month from 1 May 2025: -$48.4M published
Month from 1 Jun 2025: $10.1M published
Month from 1 Jul 2025: $3.5M published
Month from 1 Aug 2025: $2.6M published
Month from 1 Sep 2025: $8.8M published
Month from 1 Oct 2025: $32.3M published
Month from 1 Nov 2025: $7.5M published
Month from 1 Dec 2025: $8.8M published
Month from 1 Jan 2026: $5.5M published
Month from 1 Feb 2026: $1.8M published
Month from 1 Mar 2026: -$34.3M published
Month from 1 Apr 2026: $14.3M published
Month from 1 May 2026: $5.9M published
Month from 1 Jun 2026: $842K published
Month from 1 Jul 2026: $13.5M published
Month from 1 Aug 2026: $3.4M published
Month from 1 Sep 2026: $938K published
Month from 1 Oct 2026: $52.3M published
Month from 1 Nov 2026: $5.0M published
Lobbying spend
Quarter from 1 Jan 2022: $950K published
Quarter from 1 Apr 2022: $190K published
Quarter from 1 Jul 2022: $250K published
Quarter from 1 Oct 2022: $320K published
Quarter from 1 Jan 2023: $320K published
Quarter from 1 Apr 2023: $520K published
Quarter from 1 Oct 2026: $300K published
Workers in WARN layoff notices
Month from 1 Jun 2025: 121 published

What is unusual now

  • Made public in the last 90 days: it booked $57.0M in federal contract and grant obligations in October 2026, 1.3× the same month last year.
  • Federal obligations jump: booked $57.0M in federal contract and grant obligations in October 2026, 1.3× the same month last year Public on 4 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $36.5M in the last 12 months (the 12 months before: -$43.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 49 published in the last 12 months, +6.5% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 6 sales, $19.8M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Nov 2026Michael J DeppeSVP, Corp. Controller & CAOSellplanned in advance (10b5-1); after exercising options11,776$260.17$3.1MForm 4
12 Nov 2026Patrick PlewmanSVP for Diagnostic ServicesSellplanned in advance (10b5-1); after exercising options11,717$257.34$3.0MForm 4
5 Nov 2026Catherine T. DohertyExecutive Vice PresidentSellplanned in advance (10b5-1); after exercising options22,105$248.02$5.5MForm 4
28 Oct 2026Gary M PfeifferDirectorSellplanned in advance (10b5-1)1,203$243.00$292KForm 4
3 Sep 2026J. E. DavisCEO and PresidentSellplanned in advance (10b5-1)10,000$242.72$2.4MForm 4
31 Aug 2026Michael E PrevoznikSVP & General CounselSellplanned in advance (10b5-1); after exercising options22,677$243.12$5.5MForm 4
29 Jul 2026Mark E DelaneySVP & Chief Commercial OfficerSellplanned in advance (10b5-1)1,600$235.18$376KForm 4
8 Jun 2026Karthik KuppusamySVP, Clinical SolutionsSellplanned in advance (10b5-1); after exercising options8,147$200.00$1.6MForm 4

1,126 institutions reported shares at the end of Q3 2026, 93% of the shares outstanding; 117 opened a position, 79 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.9.3M8.41%$2.2B-24K-0.3%
Vanguard Capital Management LLC7.2M6.57%$1.7B-4,818-0.1%
Vanguard Portfolio Management LLC6.1M5.56%$1.4B-18K-0.3%
State Street Corp5.6M5.05%$1.3B+41K+0.7%
T. Rowe Price Associates Inc5.0M4.56%-424K-7.8%
Boston Partners4.6M4.22%$1.1B-105K-2.2%
FMR LLC (Fidelity)4.5M4.10%$1.1B+3.1M+223%
Geode Capital Management, LLC3.2M2.88%$734.9M+27K+0.9%
JPMorgan Chase & Co2.9M2.63%$669.9M-632K-18%
Morgan Stanley2.5M2.24%$575.1M+6,994+0.3%

Federal contracts

All 311 federal contracts

33 new awards in 12 months, $81.3M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
26 Oct 2026Department of Veterans Affairs$8.4MVISN 7 REF LAB SERVICES OPTION PERIOD 1 TASK ORDERUSAspending
19 Oct 2026Department of Veterans Affairs$2.7MREFERENCE LAB TESTSUSAspending
1 Oct 2026Department of Veterans Affairs$1.4MREFERENCE LABORATORYUSAspending
1 Oct 2026Department of Veterans Affairs$1.5MREFERENCE LABORATORYUSAspending
1 Oct 2026Department of Veterans Affairs$1.2MFY27 QUEST TASK ORDER. EO 14398 REQUIREMENT.USAspending
1 Oct 2026Department of Veterans Affairs$1.3MFY27 TASK ORDER. EO 14398 REQUIREMENT.USAspending
1 Oct 2026Department of Veterans Affairs$1.1MFY27 QUEST TASK ORDER. EO 14398 REQUIREMENT.USAspending
1 Oct 2026Department of Veterans Affairs$1.4MREFERENCE LAB SERVICES EO 14398 REQUIREMENT.USAspending

Company events

All 30 company events

In 12 months: 2 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
6 Oct 2026Director or officer change8-K
8 May 2026Signed a major agreement8-K
12 Mar 2026Director or officer change8-K
19 Aug 2024Signed a major agreementSame filing: changed its bylaws or fiscal year8-K
3 Jul 2024Signed a major agreement8-K
21 May 2024Director or officer change8-K
1 Nov 2023Signed a major agreement8-K
29 Sep 2023Director or officer change8-K

Reported lobbying spend: $300K in Q3 2026, $520K in Q1 2023. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
8 Feb 2023NewTarplin, Downs & Young, LLCfor Quest DiagnosticsMedicare reimbursementBudget, Health issues, Medicare/Medicaid, PharmacyFiling
31 Jan 2023EndedKing & Spalding LLPfor Quest DiagnosticsIssues related to clinical laboratory testing, including H.R. 8188 / S. 4449 - Saving Access to Laboratory Sciences Act.Health issuesFiling
15 May 2021NewKing & Spalding LLPfor Quest DiagnosticsIssues related to clinical laboratory testingHealth issuesFiling
19 Apr 2021NewFederal Street Strategies, LLCfor Quest Diagnostics IncorporatedIssues related to patient access and affordability of clinical laboratory testing.Health issues, Medicare/MedicaidFiling
1 Nov 2018NewRed+Blue Strategiesfor Quest Diagnostics IncorporatedIssues related to innovation, access and affordability of laboratory-based health care modalities in the United States.Health issues, Medicare/MedicaidFiling
5 Oct 2018EndedMcguirewoods Consulting (A Subsidiary Of Mcguirewoods LLP)for Quest Diagnostics IncorporatedNot statedFiling
29 Jun 2018EndedPolsinelli PCfor Quest DiagnosticsNot statedFiling
12 Jun 2017NewMcguirewoods Consulting (A Subsidiary Of Mcguirewoods LLP)for Quest Diagnostics IncorporatedIssues related to opioid treatmentHealth issuesFiling

Layoff notices

All 2 layoff notices

No notice in 12 months; the latest is dated 1 Jun 2025. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Jun 2025Quest Diagnostics, Inc.Montgomery, PA12126 Aug 2024closureNotice
19 Apr 2007Quest DiagnosticsCook County, IL551 Jun 2007closureNotice

The 5 newest of 354 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 May 2025confirmed

Confirmed across sources Institutional holdings and Layoff notices and Short interest and volume

Quest Diagnostics (DGX): had 4.0M shares sold short in the 30 Apr 2025 report, 1.4× the same report last year; it also saw 118 13F filers open a new position in the quarter ended 31 Mar 2025, 1.8× the same quarter last year; and it filed a WARN layoff notice covering 121 workers within 30 days. Three unrelated kinds of activity within 35 days.

  • Short interest and volume: Short interest spike, became public on 10 May 2025
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2025
  • Layoff notices: WARN layoff notice, became public on 1 Jun 2025
  • Short interest and volume: Short interest spike, became public on 28 May 2025
  • Short interest and volume: Short interest spike, became public on 11 Jun 2025
2024-04-30: 2.8M2024-05-15: 2.7M2024-05-31: 2.7M2024-06-14: 2.4M2024-06-28: 2.3M2024-07-15: 2.3M2024-07-31: 2.3M2024-08-15: 2.8M2024-08-30: 2.6M2024-09-13: 2.4M2024-09-30: 2.0M2024-10-15: 2.3M2024-10-31: 2.4M2024-11-15: 2.6M2024-11-29: 2.0M2024-12-13: 1.9M2024-12-31: 2.0M2025-01-15: 2.3M2025-01-31: 2.6M2025-02-14: 3.0M2025-02-28: 2.6M2025-03-14: 2.8M2025-03-31: 2.9M2025-04-15: 3.5M2025-04-30: 4.0M
The 30 Apr 2025 report against the 24 reports before it. this reportearliernormal: 2.5M
See the evidence (5 changes)

Short interest and volume: Short interest spike became public on 10 May 2025

Quest Diagnostics had 4.0M shares sold short in the 30 Apr 2025 report, 1.4× the same report last year.

This period
4.0M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
214K
How far from its usual level
+4.8
Same report last year
2.8M
History used
2,679 days
2024-04-30: 2.8M2024-05-15: 2.7M2024-05-31: 2.7M2024-06-14: 2.4M2024-06-28: 2.3M2024-07-15: 2.3M2024-07-31: 2.3M2024-08-15: 2.8M2024-08-30: 2.6M2024-09-13: 2.4M2024-09-30: 2.0M2024-10-15: 2.3M2024-10-31: 2.4M2024-11-15: 2.6M2024-11-29: 2.0M2024-12-13: 1.9M2024-12-31: 2.0M2025-01-15: 2.3M2025-01-31: 2.6M2025-02-14: 3.0M2025-02-28: 2.6M2025-03-14: 2.8M2025-03-31: 2.9M2025-04-15: 3.5M2025-04-30: 4.0M
the 30 Apr 2025 report24 earlier reportsnormal: 2.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2025

Quest Diagnostics saw 118 13F filers open a new position in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.

This period
118 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
58.5
Typical spread (median absolute deviation)
7
How far from its usual level
+5.7
Same quarter last year
66
History used
4,200 days
2023-03-31: 452023-06-30: 572023-09-30: 522023-12-31: 542024-03-31: 662024-06-30: 762024-09-30: 802024-12-31: 602025-03-31: 118
the quarter ended 31 Mar 20258 earlier quartersnormal: 58.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Layoff notices: WARN layoff notice became public on 1 Jun 2025

Quest Diagnostics filed a WARN layoff notice covering 121 workers within 30 days.

Notices in the window
1
Workers named
121
Window
2 May 2025 to 1 Jun 2025

Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

Short interest and volume: Short interest spike became public on 28 May 2025

Quest Diagnostics had 3.9M shares sold short in the 15 May 2025 report, 1.4× the same report last year.

This period
3.9M (the 15 May 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
214K
How far from its usual level
+4.4
Same report last year
2.7M
History used
2,694 days
2024-05-15: 2.7M2024-05-31: 2.7M2024-06-14: 2.4M2024-06-28: 2.3M2024-07-15: 2.3M2024-07-31: 2.3M2024-08-15: 2.8M2024-08-30: 2.6M2024-09-13: 2.4M2024-09-30: 2.0M2024-10-15: 2.3M2024-10-31: 2.4M2024-11-15: 2.6M2024-11-29: 2.0M2024-12-13: 1.9M2024-12-31: 2.0M2025-01-15: 2.3M2025-01-31: 2.6M2025-02-14: 3.0M2025-02-28: 2.6M2025-03-14: 2.8M2025-03-31: 2.9M2025-04-15: 3.5M2025-04-30: 4.0M2025-05-15: 3.9M
the 15 May 2025 report24 earlier reportsnormal: 2.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jun 2025

Quest Diagnostics had 3.8M shares sold short in the 30 May 2025 report, 1.4× the same report last year.

This period
3.8M (the 30 May 2025 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
216K
How far from its usual level
+4.2
Same report last year
2.7M
History used
2,709 days
2024-05-31: 2.7M2024-06-14: 2.4M2024-06-28: 2.3M2024-07-15: 2.3M2024-07-31: 2.3M2024-08-15: 2.8M2024-08-30: 2.6M2024-09-13: 2.4M2024-09-30: 2.0M2024-10-15: 2.3M2024-10-31: 2.4M2024-11-15: 2.6M2024-11-29: 2.0M2024-12-13: 1.9M2024-12-31: 2.0M2025-01-15: 2.3M2025-01-31: 2.6M2025-02-14: 3.0M2025-02-28: 2.6M2025-03-14: 2.8M2025-03-31: 2.9M2025-04-15: 3.5M2025-04-30: 4.0M2025-05-15: 3.9M2025-05-30: 3.8M
the 30 May 2025 report24 earlier reportsnormal: 2.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

21 Apr 2022confirmed

Confirmed across sources Government contracts and Lobbying

Quest Diagnostics (DGX): booked $21.9M in federal contract and grant obligations in March 2022, 7.5× the same month last year, while it lobbying on a new issue. Two unrelated kinds of activity within 8 days.

  • Government contracts: Federal obligations jump, became public on 6 Apr 2022
  • Lobbying: Lobbying on a new issue, became public on 21 Apr 2022
2017-03-01: $3.4M2018-03-01: $8.3M2019-03-01: $581K2020-03-01: $1.9M2021-03-01: $2.9M2022-03-01: $21.9M
March 2022 against the 5 months before it. this monthearliernormal: $2.9M
See the evidence (2 changes)

Government contracts: Federal obligations jump became public on 6 Apr 2022

Quest Diagnostics booked $21.9M in federal contract and grant obligations in March 2022, 7.5× the same month last year.

This period
$21.9M (March 2022)
Normal month (median of 5 earlier)
$2.9M
Typical spread (median absolute deviation)
$973K
How far from its usual level
+13.1
Same month last year
$2.9M
History used
5,295 days
2017-03-01: $3.4M2018-03-01: $8.3M2019-03-01: $581K2020-03-01: $1.9M2021-03-01: $2.9M2022-03-01: $21.9M
March 20225 earlier monthsnormal: $2.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Lobbying: Lobbying on a new issue became public on 21 Apr 2022

Quest Diagnostics lobbying on a new issue.

New
['BUD']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12725905

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

18 May 2021confirmed

Confirmed across sources Government contracts and Filings + Financials and Lobbying and Short interest and volume

Quest Diagnostics (DGX): reported revenue of $2.7B for the quarter ended 31 Mar 2021, 1.5× the same quarter last year; it also booked $12.4M in federal contract and grant obligations in May 2021, 1.7× the same month last year; it also had 9.3M shares sold short in the 15 Jun 2021 report, 2.8× the same report last year; and it reported $340K of lobbying spend for the quarter ended 30 Jun 2021, 1.5× the same quarter last year. Four unrelated kinds of activity within 112 days.

  • Financials: Quarterly revenue change, became public on 27 Apr 2021
  • Short interest and volume: Short interest spike, became public on 12 May 2021
  • Short interest and volume: Short interest spike, became public on 26 May 2021
  • Government contracts: Federal obligations jump, became public on 4 Jun 2021
  • Short interest and volume: Short interest spike, became public on 10 Jun 2021
  • Short interest and volume: Short interest spike, became public on 26 Jun 2021
  • Government contracts: Federal obligations jump, became public on 6 Jul 2021
  • Short interest and volume: Short interest spike, became public on 13 Jul 2021
  • Financials: Quarterly revenue change, became public on 27 Jul 2021
  • Lobbying: Lobbying spend jump, became public on 22 Jul 2021
  • Short interest and volume: Short interest spike, became public on 27 Jul 2021
  • Short interest and volume: Short interest spike, became public on 11 Aug 2021
2019-03-31: $1.9B2019-06-30: $2.0B2019-09-30: $2.0B2019-12-31: $1.9B2020-03-31: $1.8B2020-06-30: $1.8B2020-09-30: $2.8B2020-12-31: $3.0B2021-03-31: $2.7B
The quarter ended 31 Mar 2021 against the 8 quarters before it. this quarterearliernormal: $1.9B
See the evidence (12 changes)

Financials: Quarterly revenue change became public on 27 Apr 2021

Quest Diagnostics reported revenue of $2.7B for the quarter ended 31 Mar 2021, 1.5× the same quarter last year.

This period
$2.7B (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$1.9B
Typical spread (median absolute deviation)
$80.5M
How far from its usual level
+4.0
Same quarter last year
$1.8B
History used
4,657 days
2019-03-31: $1.9B2019-06-30: $2.0B2019-09-30: $2.0B2019-12-31: $1.9B2020-03-31: $1.8B2020-06-30: $1.8B2020-09-30: $2.8B2020-12-31: $3.0B2021-03-31: $2.7B
the quarter ended 31 Mar 20218 earlier quartersnormal: $1.9B

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 12 May 2021

Quest Diagnostics had 10.7M shares sold short in the 30 Apr 2021 report, 1.9× the same report last year.

This period
10.7M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+11.5
Same report last year
5.6M
History used
1,218 days
2020-04-30: 5.6M2020-05-15: 4.7M2020-05-29: 3.9M2020-06-15: 3.3M2020-06-30: 3.4M2020-07-15: 3.2M2020-07-31: 2.8M2020-08-14: 2.9M2020-08-31: 2.9M2020-09-15: 2.7M2020-09-30: 2.0M2020-10-15: 2.0M2020-10-30: 2.0M2020-11-13: 2.5M2020-11-30: 2.4M2020-12-15: 2.5M2020-12-31: 2.8M2021-01-15: 2.8M2021-01-29: 2.7M2021-02-12: 2.5M2021-02-26: 3.4M2021-03-15: 3.8M2021-03-31: 3.8M2021-04-15: 3.6M2021-04-30: 10.7M
the 30 Apr 2021 report24 earlier reportsnormal: 2.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 May 2021

Quest Diagnostics had 10.4M shares sold short in the 14 May 2021 report, 2.2× the same report last year.

This period
10.4M (the 14 May 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+10.9
Same report last year
4.7M
History used
1,232 days
2020-05-15: 4.7M2020-05-29: 3.9M2020-06-15: 3.3M2020-06-30: 3.4M2020-07-15: 3.2M2020-07-31: 2.8M2020-08-14: 2.9M2020-08-31: 2.9M2020-09-15: 2.7M2020-09-30: 2.0M2020-10-15: 2.0M2020-10-30: 2.0M2020-11-13: 2.5M2020-11-30: 2.4M2020-12-15: 2.5M2020-12-31: 2.8M2021-01-15: 2.8M2021-01-29: 2.7M2021-02-12: 2.5M2021-02-26: 3.4M2021-03-15: 3.8M2021-03-31: 3.8M2021-04-15: 3.6M2021-04-30: 10.7M2021-05-14: 10.4M
the 14 May 2021 report24 earlier reportsnormal: 2.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Government contracts: Federal obligations jump became public on 4 Jun 2021

Quest Diagnostics booked $12.4M in federal contract and grant obligations in May 2021, 1.7× the same month last year.

This period
$12.4M (May 2021)
Normal month (median of 5 earlier)
$1.4M
Typical spread (median absolute deviation)
$872K
How far from its usual level
+8.5
Same month last year
$7.1M
History used
4,991 days
2016-05-01: $486K2017-05-01: $1.4M2018-05-01: $1.8M2019-05-01: $02020-05-01: $7.1M2021-05-01: $12.4M
May 20215 earlier monthsnormal: $1.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Short interest and volume: Short interest spike became public on 10 Jun 2021

Quest Diagnostics had 9.8M shares sold short in the 28 May 2021 report, 2.5× the same report last year.

This period
9.8M (the 28 May 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+10.1
Same report last year
3.9M
History used
1,246 days
2020-05-29: 3.9M2020-06-15: 3.3M2020-06-30: 3.4M2020-07-15: 3.2M2020-07-31: 2.8M2020-08-14: 2.9M2020-08-31: 2.9M2020-09-15: 2.7M2020-09-30: 2.0M2020-10-15: 2.0M2020-10-30: 2.0M2020-11-13: 2.5M2020-11-30: 2.4M2020-12-15: 2.5M2020-12-31: 2.8M2021-01-15: 2.8M2021-01-29: 2.7M2021-02-12: 2.5M2021-02-26: 3.4M2021-03-15: 3.8M2021-03-31: 3.8M2021-04-15: 3.6M2021-04-30: 10.7M2021-05-14: 10.4M2021-05-28: 9.8M
the 28 May 2021 report24 earlier reportsnormal: 2.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2021

Quest Diagnostics had 9.3M shares sold short in the 15 Jun 2021 report, 2.8× the same report last year.

This period
9.3M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
464K
How far from its usual level
+9.4
Same report last year
3.3M
History used
1,264 days
2020-06-15: 3.3M2020-06-30: 3.4M2020-07-15: 3.2M2020-07-31: 2.8M2020-08-14: 2.9M2020-08-31: 2.9M2020-09-15: 2.7M2020-09-30: 2.0M2020-10-15: 2.0M2020-10-30: 2.0M2020-11-13: 2.5M2020-11-30: 2.4M2020-12-15: 2.5M2020-12-31: 2.8M2021-01-15: 2.8M2021-01-29: 2.7M2021-02-12: 2.5M2021-02-26: 3.4M2021-03-15: 3.8M2021-03-31: 3.8M2021-04-15: 3.6M2021-04-30: 10.7M2021-05-14: 10.4M2021-05-28: 9.8M2021-06-15: 9.3M
the 15 Jun 2021 report24 earlier reportsnormal: 2.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Government contracts: Federal obligations jump became public on 6 Jul 2021

Quest Diagnostics booked $7.3M in federal contract and grant obligations in June 2021, 1.0× the same month last year.

This period
$7.3M (June 2021)
Normal month (median of 5 earlier)
$1.6M
Typical spread (median absolute deviation)
$135K
How far from its usual level
+5.7
Same month last year
$7.2M
History used
5,021 days
2016-06-01: $1.5M2017-06-01: $7.1M2018-06-01: $1.5M2019-06-01: $1.6M2020-06-01: $7.2M2021-06-01: $7.3M
June 20215 earlier monthsnormal: $1.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

Check it at the source: USAspending.gov award search.

Short interest and volume: Short interest spike became public on 13 Jul 2021

Quest Diagnostics had 8.7M shares sold short in the 30 Jun 2021 report, 2.6× the same report last year.

This period
8.7M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
499K
How far from its usual level
+7.9
Same report last year
3.4M
History used
1,279 days
2020-06-30: 3.4M2020-07-15: 3.2M2020-07-31: 2.8M2020-08-14: 2.9M2020-08-31: 2.9M2020-09-15: 2.7M2020-09-30: 2.0M2020-10-15: 2.0M2020-10-30: 2.0M2020-11-13: 2.5M2020-11-30: 2.4M2020-12-15: 2.5M2020-12-31: 2.8M2021-01-15: 2.8M2021-01-29: 2.7M2021-02-12: 2.5M2021-02-26: 3.4M2021-03-15: 3.8M2021-03-31: 3.8M2021-04-15: 3.6M2021-04-30: 10.7M2021-05-14: 10.4M2021-05-28: 9.8M2021-06-15: 9.3M2021-06-30: 8.7M
the 30 Jun 2021 report24 earlier reportsnormal: 2.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 27 Jul 2021

Quest Diagnostics reported revenue of $2.5B for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.

This period
$2.5B (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$2.0B
Typical spread (median absolute deviation)
$130.0M
How far from its usual level
+3.0
Same quarter last year
$1.8B
History used
4,748 days
2019-06-30: $2.0B2019-09-30: $2.0B2019-12-31: $1.9B2020-03-31: $1.8B2020-06-30: $1.8B2020-09-30: $2.8B2020-12-31: $3.0B2021-03-31: $2.7B2021-06-30: $2.5B
the quarter ended 30 Jun 20218 earlier quartersnormal: $2.0B

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Lobbying: Lobbying spend jump became public on 22 Jul 2021

Quest Diagnostics reported $340K of lobbying spend for the quarter ended 30 Jun 2021, 1.5× the same quarter last year.

This period
$340K (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$220K
Typical spread (median absolute deviation)
$10K
How far from its usual level
+5.5
Same quarter last year
$230K
History used
4,018 days
2019-06-30: $240K2019-09-30: $210K2019-12-31: $170K2020-03-31: $210K2020-06-30: $230K2020-09-30: $220K2020-12-31: $220K2021-03-31: $230K2021-06-30: $340K
the quarter ended 30 Jun 20218 earlier quartersnormal: $220K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Short interest and volume: Short interest spike became public on 27 Jul 2021

Quest Diagnostics had 8.1M shares sold short in the 15 Jul 2021 report, 2.5× the same report last year.

This period
8.1M (the 15 Jul 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
499K
How far from its usual level
+7.1
Same report last year
3.2M
History used
1,294 days
2020-07-15: 3.2M2020-07-31: 2.8M2020-08-14: 2.9M2020-08-31: 2.9M2020-09-15: 2.7M2020-09-30: 2.0M2020-10-15: 2.0M2020-10-30: 2.0M2020-11-13: 2.5M2020-11-30: 2.4M2020-12-15: 2.5M2020-12-31: 2.8M2021-01-15: 2.8M2021-01-29: 2.7M2021-02-12: 2.5M2021-02-26: 3.4M2021-03-15: 3.8M2021-03-31: 3.8M2021-04-15: 3.6M2021-04-30: 10.7M2021-05-14: 10.4M2021-05-28: 9.8M2021-06-15: 9.3M2021-06-30: 8.7M2021-07-15: 8.1M
the 15 Jul 2021 report24 earlier reportsnormal: 2.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Aug 2021

Quest Diagnostics had 7.2M shares sold short in the 30 Jul 2021 report, 2.6× the same report last year.

This period
7.2M (the 30 Jul 2021 report)
Normal report (median of 24 earlier)
2.8M
Typical spread (median absolute deviation)
636K
How far from its usual level
+4.6
Same report last year
2.8M
History used
1,309 days
2020-07-31: 2.8M2020-08-14: 2.9M2020-08-31: 2.9M2020-09-15: 2.7M2020-09-30: 2.0M2020-10-15: 2.0M2020-10-30: 2.0M2020-11-13: 2.5M2020-11-30: 2.4M2020-12-15: 2.5M2020-12-31: 2.8M2021-01-15: 2.8M2021-01-29: 2.7M2021-02-12: 2.5M2021-02-26: 3.4M2021-03-15: 3.8M2021-03-31: 3.8M2021-04-15: 3.6M2021-04-30: 10.7M2021-05-14: 10.4M2021-05-28: 9.8M2021-06-15: 9.3M2021-06-30: 8.7M2021-07-15: 8.1M2021-07-30: 7.2M
the 30 Jul 2021 report24 earlier reportsnormal: 2.8M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 4 Nov 2026Government contracts change

    booked $57.0M in federal contract and grant obligations in October 2026, 1.3× the same month last year.

    Same month last year: $42.6M; its normal month is $35.6M.

    See the evidence
    This period
    $57.0M (October 2026)
    Normal month (median of 5 earlier)
    $35.6M
    Typical spread (median absolute deviation)
    $929K
    How far from its usual level
    +6.0
    Same month last year
    $42.6M
    History used
    6,970 days
    2021-10-01: $40.1M2022-10-01: $35.6M2023-10-01: $35.5M2024-10-01: $34.6M2025-10-01: $42.6M2026-10-01: $57.0M
    October 20265 earlier monthsnormal: $35.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  2. 1 Nov 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24727N0015 ($8.4M) (dated 26 Oct 2026)

  3. 25 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24827N0103 ($2.7M) (dated 19 Oct 2026)

  4. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26227N0107 ($1.4M) (dated 1 Oct 2026)

  5. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26227N0087 ($1.5M) (dated 1 Oct 2026)

  6. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26127N0040 ($1.2M) (dated 1 Oct 2026)

  7. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26127N0039 ($1.3M) (dated 1 Oct 2026)

  8. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26127N0037 ($1.1M) (dated 1 Oct 2026)

  9. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26127N0006 ($1.4M) (dated 1 Oct 2026)

  10. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25227N0098 ($7.2M) (dated 1 Oct 2026)

  11. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25227N0090 ($3.1M) (dated 1 Oct 2026)

  12. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24827N0084 ($2.1M) (dated 1 Oct 2026)

  13. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24827N0042 ($1.6M) (dated 1 Oct 2026)

  14. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24827N0033 ($2.7M) (dated 1 Oct 2026)

  15. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24827N0029 ($2.0M) (dated 1 Oct 2026)

  16. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24827N0025 ($1.5M) (dated 1 Oct 2026)

  17. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24527N0043 ($2.2M) (dated 1 Oct 2026)

  18. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24527N0041 ($2.7M) (dated 1 Oct 2026)

  19. 7 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24527N0039 ($1.9M) (dated 1 Oct 2026)

  20. 6 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 6 Oct 2026Filings record

    Director or officer change

  22. 5 Oct 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C10X26F0094 ($3.5M) (dated 29 Sep 2026)

  23. 6 Jul 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25226N0464 ($1.0M) (dated 30 Jun 2026)

  24. 7 May 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25226N0411 ($2.6M) (dated 1 May 2026)

  25. 27 Apr 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24626N0657 ($1.6M) (dated 21 Apr 2026)

  26. 12 Apr 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24626N0576 ($1.4M) (dated 6 Apr 2026)

  27. 8 Apr 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24626N0580 ($2.1M) (dated 2 Apr 2026)

  28. 8 Apr 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24626N0574 ($2.7M) (dated 2 Apr 2026)

  29. 7 Apr 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25226N0362 ($3.1M) (dated 1 Apr 2026)

  30. 30 Mar 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24726P0300 ($4.7M) (dated 24 Mar 2026)

  31. 12 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 12 Mar 2026Filings record

    Director or officer change

  33. 9 Mar 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25726N0210 ($2.5M) (dated 3 Mar 2026)

  34. 5 Mar 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25726N0235 ($2.6M) (dated 27 Feb 2026)

  35. 4 Mar 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26026N0207 ($1.5M) (dated 26 Feb 2026)

  36. 5 Feb 2026Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C26126N0314 ($1.0M) (dated 30 Jan 2026)

  37. 22 Dec 2025Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24226N0280 ($1.8M) (dated 16 Dec 2025)

  38. 8 Dec 2025Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C25726N0121 ($1.5M) (dated 2 Dec 2025)

  39. 19 Nov 2025Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24626N0319 ($1.0M) (dated 13 Nov 2025)

  40. 3 Nov 2025Government contracts record

    QUEST DIAGNOSTICS INCORPORATED: new Department of Veterans Affairs contract 36C24826N0124 ($2.7M) (dated 28 Oct 2025)

Showing the newest 40 of 178 entries; narrow the window or the kind of data to see older ones.

Not listed: 313 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001022079
Ticker
DGX
Domain
questdiagnostics.com
Employer name
AmeriPath Indianapolis, P.C, Quest Diagnostics Incorporated (2 unverified)
Fein
35-2037910 (1 unverified)
Hq location
NJ|SECAUCUS|07094 (1 unverified)
Lobbying client
quest diagnostics
Name
100% American Medical Laboratories, Incorporated (DE), 100% AmeriPath Cincinnati, Inc. (OH), 100% AmeriPath Cleveland, Inc. (OH), 100% AmeriPath Consolidated Labs, Inc. (FL) and 82 more
Uei
CCYYREJXLFE3, GLPMEN5F8LZ1, NBHKGGN6DL95, R4SRLXUNDJK8 and 3 more
Wikidata
Q7271456
Wikipedia
Quest Diagnostics
  • DOL H-1B labor condition applications and PERM certifications1033 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)18 records, 240 data points30 Jun 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)157 records28 Jan 2016 to 23 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1141 data points31 Dec 2006 to 15 Oct 2026
  • SEC Form 4 insider transactions178 records, 524 data points3 Mar 2016 to 16 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards311 records, 14400 data points1 Oct 2007 to 19 Nov 2026
  • WARN layoff notices (state labor agencies)2 records, 6 data points16 Apr 2007 to 1 Jun 2025
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026